Suzhou, China

Xianqi Kong

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Risen (Suzhou) Pharma Tech Co., Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xianqi Kong. Retrieved from https://idiyas.com/inventor/xianqi-kong-4zey150b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xianqi Kong: Innovator in Pharmaceutical Chemistry

Introduction

Xianqi Kong is a notable inventor based in Suzhou, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on crystalline compounds.

Latest Patents

Xianqi Kong holds a patent for a crystalline form of 3-((L-valyl) amino)-1-propanesulfonic acid. This invention relates to the preparation method and various uses of this compound, showcasing his expertise in developing new pharmaceutical formulations.

Career Highlights

Kong is currently employed at Risen (Suzhou) Pharma Tech Co., Ltd., where he continues to advance his research and development efforts. His work has been instrumental in enhancing the efficacy of pharmaceutical products.

Collaborations

He collaborates with talented coworkers such as Jiasheng Lu and Jiamin Gu, contributing to a dynamic research environment that fosters innovation.

Conclusion

Xianqi Kong's contributions to pharmaceutical chemistry through his patent and work at Risen Pharma highlight his role as a key innovator in the industry. His ongoing research promises to lead to further advancements in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…